Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › KNSA
RICE HALL JAMES & ASSOCIATES, LLC position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 466,050 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q3 2026 13F filing — a position valued at US$34.8M, representing 1.84% of its reported portfolio and ranking #10 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed KNSA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's KNSA position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in KNSA in Q3 2023 at 650,366 shares (US$11.3M). The position peaked in Q2 2026 at 624,928 shares, worth US$40.0M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 466,050 shares valued at US$34.8M — a reduction of -158,878 shares quarter over quarter.. Notable position changes include a 25% trim in Q3 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 650.37K | $11.30M | New |
| Q4 2023 | 636.03K | $11.16M | Reduce |
| Q1 2024 | 618.80K | $12.21M | Reduce |
| Q2 2024 | 600.63K | $11.21M | Reduce |
| Q3 2024 | 649.63K | $16.23M | Add |
| Q4 2024 | 642.75K | $12.71M | Reduce |
| Q1 2025 | 624.54K | $13.87M | Reduce |
| Q2 2025 | 638.23K | $17.66M | Add |
| Q3 2025 | 577.82K | $22.44M | Reduce |
| Q4 2025 | 596.43K | $24.60M | Add |
| Q1 2026 | 608.42K | $29.30M | Add |
| Q2 2026 | 624.93K | $39.96M | Add |
| Q3 2026 | 466.05K | $34.77M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 49 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $68.50M · Q3 2026
- OBERWEIS ASSET MANAGEMENT INC/ 410.91K sh · $30.66M · Q3 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 347.66K sh · $25.97M · Q3 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 198.67K sh · $14.82M · Q3 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held KNSA?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed KNSA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in KNSA?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 466.05K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $34.77M, representing 1.84% of its reported portfolio and ranking #10.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling KNSA?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in KNSA. The position peaked in Q2 2026 at 624.93K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.